Literature DB >> 27580536

The Long-term Clinical Course of Chronic Eosinophilic Pneumonia.

Takashi Ishiguro1, Noboru Takayanagi, Ryuji Uozumi, Mami Tada, Naho Kagiyama, Yotaro Takaku, Yoshihiko Shimizu, Yutaka Sugita, Satoshi Morita.   

Abstract

Objective The long-term clinical course and prognosis of patients with chronic eosinophilic pneumonia (CEP) including factors predictive of the relapse of CEP have not been fully investigated. The aim of the present study was to investigate these issues. Methods We retrospectively investigated the rate of relapse and prognosis in 73 patients diagnosed as having CEP. Results Systemic corticosteroid therapy was administered at a prednisolone dose of 29.4±7.6 mg/day. During a median follow-up period of 1,939 days, 27 patients suffered from relapse of CEP. Two patients developed steroid-induced diabetes mellitus, and 1 patient developed pulmonary nontuberculous mycobacteriosis. Five patients died; however, none died of CEP. A history of smoking was the only independent negative risk factor for relapse of CEP [hazard ratio, 0.37 (0.14-0.98)]. Conclusion Patients with CEP frequently relapse. During the follow-up, metabolic and infectious complications under prolonged corticosteroid therapy are problematic. A history of smoking was a negative factor for predicting the risk of CEP relapse.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27580536     DOI: 10.2169/internalmedicine.55.6765

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Idiopathic Chronic Eosinophilic Pneumonia Evolving to Pulmonary Fibrosis: A Retrospective Analysis.

Authors:  Misbah Baqir; Tobias Peikert; Tucker F Johnson; Yasmeen K Tandon; Eunhee S Yi; Darrell R Schroeder; Jay H Ryu
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

2.  Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids.

Authors:  Christopher Chan; David DeLapp; Perry Nystrom
Journal:  Respir Med Case Rep       Date:  2017-05-31

3.  Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.

Authors:  Hiroki Tashiro; Koichiro Takahashi; Yuki Kurihara; Hironori Sadamatsu; Yuki Kuwahara; Shinya Kimura; Naoko Sueoka-Aragane
Journal:  J Asthma Allergy       Date:  2022-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.